CN111886248B - GM-CSF或GM-CSF受体的配体用于在已接受Allo-HCT的患者中治疗恶性血液病 - Google Patents

GM-CSF或GM-CSF受体的配体用于在已接受Allo-HCT的患者中治疗恶性血液病 Download PDF

Info

Publication number
CN111886248B
CN111886248B CN201980020251.7A CN201980020251A CN111886248B CN 111886248 B CN111886248 B CN 111886248B CN 201980020251 A CN201980020251 A CN 201980020251A CN 111886248 B CN111886248 B CN 111886248B
Authority
CN
China
Prior art keywords
cells
csf
leukemia
mice
hct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980020251.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111886248A (zh
Inventor
S·图格斯
B·比彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18194549.4A external-priority patent/EP3623382A1/en
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of CN111886248A publication Critical patent/CN111886248A/zh
Application granted granted Critical
Publication of CN111886248B publication Critical patent/CN111886248B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980020251.7A 2018-02-22 2019-02-22 GM-CSF或GM-CSF受体的配体用于在已接受Allo-HCT的患者中治疗恶性血液病 Active CN111886248B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18158169 2018-02-22
EP18158169.5 2018-02-22
EP18189562 2018-08-17
EP18189562.4 2018-08-17
EP18194549.4 2018-09-14
EP18194549.4A EP3623382A1 (en) 2018-09-14 2018-09-14 Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US16/269,572 US11655293B2 (en) 2018-02-22 2019-02-07 Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US16/269,572 2019-02-07
PCT/EP2019/054493 WO2019162472A1 (en) 2018-02-22 2019-02-22 Ligands to gm-csf or gm-csf-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-hct

Publications (2)

Publication Number Publication Date
CN111886248A CN111886248A (zh) 2020-11-03
CN111886248B true CN111886248B (zh) 2025-03-04

Family

ID=67616687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980020251.7A Active CN111886248B (zh) 2018-02-22 2019-02-22 GM-CSF或GM-CSF受体的配体用于在已接受Allo-HCT的患者中治疗恶性血液病

Country Status (11)

Country Link
US (3) US11655293B2 (enExample)
EP (1) EP3755715A1 (enExample)
JP (1) JP7278296B2 (enExample)
KR (1) KR20200123434A (enExample)
CN (1) CN111886248B (enExample)
AU (1) AU2019224550A1 (enExample)
BR (1) BR112020017253A2 (enExample)
CA (1) CA3091536A1 (enExample)
MA (1) MA51893A (enExample)
MX (2) MX2020008792A (enExample)
WO (1) WO2019162472A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
MX2022011111A (es) * 2020-03-08 2023-03-02 Humanigen Inc Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.
CA3229748A1 (en) * 2021-08-26 2023-03-02 Akifumi Kato Bispecific antibody that binds to cd116 and cd131

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501070A (zh) * 2006-02-08 2009-08-05 诺福泰克公司 抗原性gm-csf肽和针对gm-csf的抗体
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1367688A (zh) 1999-04-14 2002-09-04 美国政府卫生与公众服务部 用于诱导对移植物的免疫耐受性的、包含免疫毒素和抑制树突细胞成熟的因子的组合物
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
RU2447085C2 (ru) 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
MX2008012291A (es) 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
CA2717987C (en) 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
MA37946B1 (fr) 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
US9658228B2 (en) * 2013-01-30 2017-05-23 The Board of Trustees of the Leland University Junior University Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients
JP6490419B2 (ja) 2014-12-24 2019-03-27 学校法人関西医科大学 制御性ｔ細胞分化誘導剤
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501070A (zh) * 2006-02-08 2009-08-05 诺福泰克公司 抗原性gm-csf肽和针对gm-csf的抗体
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途

Also Published As

Publication number Publication date
JP7278296B2 (ja) 2023-05-19
BR112020017253A2 (pt) 2020-12-22
MX2020008792A (es) 2020-10-14
RU2020129401A (ru) 2022-03-22
JP2021514368A (ja) 2021-06-10
US20210070851A1 (en) 2021-03-11
US11655293B2 (en) 2023-05-23
RU2020129401A3 (enExample) 2022-03-22
US20190256587A1 (en) 2019-08-22
MA51893A (fr) 2020-12-30
KR20200123434A (ko) 2020-10-29
EP3755715A1 (en) 2020-12-30
CA3091536A1 (en) 2019-08-29
WO2019162472A1 (en) 2019-08-29
US20230340100A1 (en) 2023-10-26
MX2023001357A (es) 2023-02-27
US12384839B2 (en) 2025-08-12
AU2019224550A1 (en) 2020-09-17
CN111886248A (zh) 2020-11-03

Similar Documents

Publication Publication Date Title
JP6808688B2 (ja) Ｔ制御性細胞の増殖または枯渇方法
Cravedi et al. Immune cell-derived C3a and C5a costimulate human T cell alloimmunity
US12384839B2 (en) Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
JP5525689B2 (ja) 過剰増殖性障害を処置するための組成物および方法
US20100291677A1 (en) Reducer of immunosuppression by tumor cell and antitumor agent using the same
US20200095321A1 (en) Methods for in vivo expansion of cd8+ t cells and prevention or treatment of gvhd
US20220241333A1 (en) Modulation of t cell cytotoxicity and related therapy
ES2912173T3 (es) Terapia celular basada en NK mejorada
US20220411500A1 (en) Treatment of fibrosis with combined blockade of il-6 and immune checkpoint
JP2021521121A (ja) 自己免疫疾患を処置するための方法
US20240226168A1 (en) Engineered nk cells and uses thereof
RU2772132C2 (ru) Лиганды гм-ксф или рецептора гм-ксф для применения при лечении гемобластоза у пациента, перенесшего алло-тгк
Li et al. Treatment of a MyD88 inhibitor alleviates rejection and inflammation in xenotransplantation by inhibiting dendritic cells activation and trained immunity in macrophages
EP3623382A1 (en) Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
Choi et al. Context-dependent roles for autophagy in myeloid cells in tumor progression
WO2024014523A1 (en) Anti-aqp3 antibody cancer therapy
Dou et al. Reconstituted CD74+ NK cells trigger chronic graft versus host disease after allogeneic bone marrow transplantation
Simms Investigating the crosstalk between hepatic stellate cells and antigen presenting cells in pancreatic cancer liver metastases
WO2024050517A1 (en) Methods of making and using anticancer reprogrammed b cells
AU2022209669A1 (en) T cells for use in therapy
WO2024064724A1 (en) Compositions and methods for treating cancer
Loo Activation of natural killer T cells and dendritic cells with Caulobacter crescentus: Implications for developing tumour immunity
HK1138021B (en) Compositions and methods for the treatment of infections and tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20390610